Menopause & midlife

Progesterone vs Progestins: Not the Same Thing

Save

Micronized progesterone is body-identical to the hormone the ovaries make, while progestins like medroxyprogesterone acetate are synthetic look-alikes. Both protect the uterine lining, but the breast-cancer signal in older trials came from an estrogen-plus-progestin arm. Some observational data suggest progesterone may carry a lower association, though the evidence is limited.

Last updated: July 2026

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

What is the difference between progesterone and a progestin?

Progesterone is the hormone a woman's ovaries produce; progestins are synthetic molecules built to act like it. Micronized progesterone, sold as Prometrium and often described as body-identical, has the same chemical structure as natural progesterone, milled into fine particles the gut can absorb.

Progestins such as medroxyprogesterone acetate, the compound in Provera, differ slightly in structure and can bind other hormone receptors, so their side-effect profiles are not interchangeable. According to an Endocrine Society guideline, both classes reliably protect the uterine lining, so the choice often turns on tolerability and risk nuance rather than endometrial safety 1. The 2022 Menopause Society statement lists both as acceptable options 2.

Why does the Women's Health Initiative matter here?

The Women's Health Initiative tested one specific combination, not hormone therapy in general. Its combined arm used conjugated equine estrogen plus medroxyprogesterone acetate, a synthetic progestin, and it was that pairing that raised the early alarms about breast cancer and cardiovascular risk in 2002 3.

The trial enrolled women who were on average 63 years old, many of them well past menopause, which further shaped the results 3. Because the progestin, the estrogen, the dose, and the population were all fixed in that study, its findings cannot be assumed to apply identically to micronized progesterone or to transdermal estradiol used today. That nuance is central to reading the data honestly.

Do the two carry different breast-cancer signals?

Breast-cancer risk in the major trials clustered in the estrogen-plus-progestin arm rather than the estrogen-alone arm. In long-term Women's Health Initiative follow-up, combined estrogen-progestin therapy was linked to a modest rise in breast-cancer incidence, while estrogen alone was associated with a lower incidence 4.

In absolute terms the combined-therapy excess was small, fewer than 1 extra case per 1,000 women each year, and the signal emerged mainly after about 3 to 5 years of use 42. Some observational studies suggest micronized progesterone may carry a lower breast-cancer association than certain synthetic progestins, but the Menopause Society describes this evidence as limited and largely non-randomized 2. Reading hormone replacement therapy risk data in absolute numbers keeps the picture in proportion.

How are the two alike?

Both micronized progesterone and synthetic progestins share the same core job: shielding the uterine lining from estrogen-driven overgrowth 5. Either one, added to systemic estrogen, sharply lowers the risk of endometrial hyperplasia, so on that measure they are equivalent 1.

In perimenopause, when the ovaries still release estrogen unevenly, a progestogen may be given cyclically to trigger a monthly bleed; after menopause a continuous daily approach is more common, and both molecules can be used either way 2. Side effects such as bloating, breast tenderness, or mood changes can differ between them, which is why some people who tolerate one poorly do better on the other. Overall menopause symptoms and sleep quality often guide the pick.

When progestogen choices need a menopause clinician

A menopause-focused clinician can match the progestogen to your symptoms, sleep, and personal risk profile. They can weigh whether body-identical micronized progesterone or a specific progestin fits best, and adjust if side effects appear 2. That conversation applies squarely to healthy women under 60 or within 10 years of menopause, where benefits generally outweigh risks 2.

Because the breast-cancer nuance rests on limited and evolving evidence, an individualized plan beats any blanket rule 4. If one progestogen causes bloating, low mood, or breast tenderness, switching to the other is often a reasonable next step rather than stopping protection altogether 1. Gale can help you gather your history before that appointment.

Common questions

The honest answer is that the evidence is incomplete. Some observational studies suggest micronized progesterone may carry a lower breast-cancer association than certain synthetic progestins, but this has not been proven in randomized trials, and both protect the uterine lining equally well.

Yes. Prometrium is a brand of micronized progesterone, which is body-identical, meaning structurally the same as the progesterone the ovaries make. It is FDA-approved, unlike custom-compounded preparations.

The trial, designed in the 1990s, used conjugated estrogen plus medroxyprogesterone acetate because that was the common combination at the time. Its breast-cancer and heart findings reflect that specific pairing and an older study population, not every regimen used today.

Many people do, often to reduce side effects like bloating or low mood. Because both protect the lining, a clinician can compare options and change the type or schedule while keeping the estrogen dose steady.

Related

Say it back

How would you explain this to someone you love?

Two or three sentences, just as you’d say it. Gale reflects back what you focused on — a mirror, not a quiz.

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

Signs that need a clinician's eye

  • —New or unexplained vaginal bleeding after menopause, or bleeding that persists beyond the first few months of therapy, is a reason to seek clinician review.
  • —A new breast lump, skin dimpling, or nipple change is a reason to arrange prompt evaluation regardless of which progestogen you use.
  • —Persistent low mood, or mood changes that interfere with daily life, is a reason to seek clinician review, and if thoughts of self-harm arise, to contact the 988 Suicide and Crisis Lifeline.
  • —Sudden leg swelling, calf pain, or shortness of breath warrants urgent medical care to rule out a blood clot.

This article is general health education, not medical advice. Whether micronized progesterone or a synthetic progestin suits you depends on your history and symptoms and should be decided with a gynecologist or menopause clinician.

References

  1. 1.Stuenkel CA, et al. (Endocrine Society) (2015). Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism. doi:10.1210/jc.2015-2236 ✓Endocrine Society clinical practice guideline that both micronized progesterone and synthetic progestins protect the endometrium, framing the choice around tolerability rather than lining safety.
  2. 2.The North American Menopause Society (Menopause Society) (2022). The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. doi:10.1097/GME.0000000000002028 ✓The 2022 Menopause Society position statement listing progesterone and progestins as acceptable options, characterizing the lower-risk evidence for micronized progesterone as limited, and supporting therapy for healthy women under 60 or within 10 years of menopause.
  3. 3.Rossouw JE, Anderson GL, Prentice RL, et al. / Writing Group for the Women's Health Initiative Investigators (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. doi:10.1001/jama.288.3.321 ✓The 2002 Women's Health Initiative principal results, showing the combined conjugated-estrogen-plus-medroxyprogesterone-acetate regimen in an older population (average age 63) raised the initial breast-cancer and cardiovascular alarms.
  4. 4.Chlebowski RT, Anderson GL, Aragaki AK, et al. (2020). Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the Women's Health Initiative randomized clinical trials. JAMA. doi:10.1001/jama.2020.9482 ✓Long-term Women's Health Initiative follow-up, showing combined estrogen-progestin therapy raised breast-cancer incidence modestly while estrogen alone lowered it, with a small absolute excess emerging after several years of use.
  5. 5.MedlinePlus (National Library of Medicine) (2026). Hormone Replacement Therapy. MedlinePlus, U.S. National Library of Medicine (NIH). link ✓Patient-facing NIH overview describing progesterone and progestin use with estrogen and the forms available.

5 sources, numbered by first appearance. General health information, not medical advice. AI-assisted editorial content — every citation independently verified. Editorial policy

← Back to the health library